1. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing
- Author
-
Yoshiko Nanki, Tatsuyuki Chiyoda, Wataru Yamagami, Aki Ookubo, Manabu Itoh, Daisuke Aoki, Kaori Kameyama, Fumio Kataoka, Akira Hirasawa, Masaru Ueno, and Tomoko Akahane
- Subjects
endocrine system diseases ,lcsh:Medicine ,Antineoplastic Agents ,Article ,Olaparib ,chemistry.chemical_compound ,Ovarian cancer ,Organoid ,Humans ,Medicine ,Precision Medicine ,Cancer models ,lcsh:Science ,Ovarian Neoplasms ,Gynaecological cancer ,Multidisciplinary ,Genome, Human ,business.industry ,lcsh:R ,Cancer ,medicine.disease ,Organoids ,Serous fluid ,chemistry ,Paclitaxel ,Drug Resistance, Neoplasm ,PARP inhibitor ,Cancer research ,Female ,lcsh:Q ,business ,Clear cell - Abstract
The use of primary patient-derived organoids for drug sensitivity and resistance testing could play an important role in precision cancer medicine. We developed expandable ovarian cancer organoids in BRCA1 pathogenic variant (p.L63*) showed a higher sensitivity to PARP inhibitor, olaparib, as well as to platinum drugs compared to the other organoids, whereas an organoid derived from clear cell ovarian cancer was resistant to conventional drugs for ovarian cancer, namely platinum drugs, paclitaxel, and olaparib. The overall success rate of primary organoid culture, including those of various histological subtypes, was 80% (28/35). Our data show that patient-derived organoids are suitable physiological ex vivo cancer models that can be used to screen effective personalised ovarian cancer drugs.
- Published
- 2020
- Full Text
- View/download PDF